Foghorn Therapeutics (FHTX) Competitors $3.57 -0.02 (-0.56%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.58 +0.01 (+0.14%) As of 04/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. ETNB, CMRX, CDMO, RCUS, VIR, MLYS, PAHC, SYRE, NRIX, and ZYMEShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include 89bio (ETNB), Chimerix (CMRX), Avid Bioservices (CDMO), Arcus Biosciences (RCUS), Vir Biotechnology (VIR), Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), Spyre Therapeutics (SYRE), Nurix Therapeutics (NRIX), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. 89bio Chimerix Avid Bioservices Arcus Biosciences Vir Biotechnology Mineralys Therapeutics Phibro Animal Health Spyre Therapeutics Nurix Therapeutics Zymeworks 89bio (NASDAQ:ETNB) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Does the media prefer ETNB or FHTX? In the previous week, 89bio had 9 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 11 mentions for 89bio and 2 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.81 beat 89bio's score of 0.72 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 89bio 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, ETNB or FHTX? Foghorn Therapeutics has higher revenue and earnings than 89bio. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89bioN/AN/A-$142.19M-$3.43-1.76Foghorn Therapeutics$22.60M8.78-$98.43M-$1.65-2.16 Do analysts prefer ETNB or FHTX? 89bio currently has a consensus price target of $27.56, indicating a potential upside of 355.46%. Foghorn Therapeutics has a consensus price target of $13.17, indicating a potential upside of 268.81%. Given 89bio's higher possible upside, research analysts clearly believe 89bio is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89bio 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ETNB or FHTX more profitable? 89bio has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat 89bio's return on equity.Company Net Margins Return on Equity Return on Assets 89bioN/A -59.58% -52.21% Foghorn Therapeutics -357.53%N/A -30.98% Do insiders and institutionals have more ownership in ETNB or FHTX? 61.5% of Foghorn Therapeutics shares are held by institutional investors. 2.8% of 89bio shares are held by company insiders. Comparatively, 9.1% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, ETNB or FHTX? 89bio has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.16, meaning that its share price is 216% more volatile than the S&P 500. Does the MarketBeat Community prefer ETNB or FHTX? 89bio received 73 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. However, 64.06% of users gave Foghorn Therapeutics an outperform vote while only 62.98% of users gave 89bio an outperform vote. CompanyUnderperformOutperform89bioOutperform Votes11462.98% Underperform Votes6737.02% Foghorn TherapeuticsOutperform Votes4164.06% Underperform Votes2335.94% SummaryFoghorn Therapeutics beats 89bio on 12 of the 17 factors compared between the two stocks. Remove Ads Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$198.54M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.866.7921.7317.82Price / Sales8.78225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book-1.955.866.464.00Net Income-$98.43M$141.86M$3.20B$247.23M7 Day Performance0.85%4.50%2.86%1.45%1 Month Performance-19.41%-12.65%-8.55%-6.24%1 Year Performance-40.80%-11.06%10.47%0.60% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.238 of 5 stars$3.57-0.6%$13.17+268.8%-44.1%$198.54M$22.60M-1.86120News CoverageGap DownETNB89bio2.5885 of 5 stars$5.49-4.9%$27.56+401.9%-36.2%$801.45MN/A-1.8940Short Interest ↑News CoverageHigh Trading VolumeCMRXChimerix2.9082 of 5 stars$8.52-0.1%$8.53+0.2%+834.8%$799.21M$212,000.00-9.0690CDMOAvid Bioservices0.7966 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320High Trading VolumeRCUSArcus Biosciences2.4498 of 5 stars$7.28+5.9%$30.25+315.8%-50.9%$764.88M$258M-2.31500High Trading VolumeVIRVir Biotechnology2.6735 of 5 stars$5.52-1.1%$35.67+546.1%-34.4%$757.03M$63.71M-1.41580Short Interest ↑MLYSMineralys Therapeutics2.3958 of 5 stars$12.05-2.8%$33.00+173.9%+12.5%$756.56MN/A-3.3128Insider TradeShort Interest ↑Gap UpHigh Trading VolumePAHCPhibro Animal Health3.8284 of 5 stars$18.66-2.8%$21.00+12.5%+27.3%$755.79M$1.11B38.881,860SYRESpyre Therapeutics1.8047 of 5 stars$12.39-3.1%$50.33+306.2%-65.8%$746.58M$890,000.00-1.66100High Trading VolumeNRIXNurix Therapeutics2.1174 of 5 stars$9.72+0.3%$30.88+217.7%-36.5%$741.01M$54.55M-3.36300Gap DownHigh Trading VolumeZYMEZymeworks2.6506 of 5 stars$10.43-4.7%$21.00+101.3%+20.4%$725.69M$76.30M-6.95460Positive News Remove Ads Related Companies and Tools Related Companies 89bio Competitors Chimerix Competitors Avid Bioservices Competitors Arcus Biosciences Competitors Vir Biotechnology Competitors Mineralys Therapeutics Competitors Phibro Animal Health Competitors Spyre Therapeutics Competitors Nurix Therapeutics Competitors Zymeworks Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
